Manufacturer of Immune Regulation Proteins
Your Position : Home > Products > Growth Factors > cEPO (human):Fc (human) (rec.) (non-lytic)
Product

cEPO (human):Fc (human) (rec.) (non-lytic)

Product Data

Synonyms :  

cEPO

Properties

Host : 

CHO cell 

Sequence :

The extracellular domain of human cEPO(NP_000790.2)(Pro30-Arg193) (Arg103Glu) 

is fused to the N-terminus of the Fc region of a mutant human IgG1.

Molecular Mass:

44KDa (monomer)

Non-lytic:

Acts as a long lasting fusion protein which only binds to the receptor. 

Mutations to the complement (C1q) and FcgR I binding sites of the IgGs Fc fragment 

render the fusion proteins incapable of antibody directed cytotoxicity (ADCC) and complement directed cytotoxicity (CDC).

 

 

Purity :

>98%by SDS-PAGE under reducing conditions 

Endotoxin Content :

<60 EU/mg as determined by LAL test.

 

Activity:

Measured by the dose-dependant stimulation of human megakaryoblastic leukemia cells.

Shipping and Handling

Formulation : 

Lyophilized from 0.2 μm-filtered solution in PBS.

Reconstitution :

Reconstitute at 100 μg/ml in sterile PBS.

Use / Stability :

 

Stable for at least 1 year after receipt when stored 

at -20°C. Working aliquots are stable for up to 3 months 

when stored at -20°C.

                        Avoid freeze/thaw cycles.

Documents
Description

Erythropoietin (EPO), a glycoprotein produced primarily by the kidney, is the principal factor that regulates erythropoiesis bystimulating the proliferation and differentiation of erythroid progenitor cells. The production of EPO by kidney cells is increased in response to hypoxia or anemia. Recombinant EPO has been approved for the treatment of anemia associated with chronic renal failure as well as for anemia of AZT treated AIDS patients. EPO (human):Fc (human) (rec.) (non-lytic) is a long-acting version of EPO.

Online Message